m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00572
 [1], [2], [3], [4]
m6A modification pri-miR-143 pri-miR-143 METTL3 Methylation : m6A sites Indirect Inhibition RNA modification HIF1A HIF1A YBX1 : modification sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target pri-miR-143
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> 5-methylcytidine (m5C)
Epigenetic Regulator Y-box-binding protein 1 (YBX1) READER View Details
Regulated Target Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A) View Details
Crosstalk Relationship m6A  →  m5C Inhibition
Crosstalk Mechanism m6A modification indirectly impacts RNA modification through downstream signaling pathways
Crosstalk Summary METTL3 interacts with pri-miR-143, reading its m6A level and inhibiting its physical interaction with Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A), which was regulated by YBX1-mediated m5C modification.
In-vitro Model
 T24 Bladder carcinoma Homo sapiens CVCL_0554
TCCSUP Bladder carcinoma Homo sapiens CVCL_1738
NCI-H1975 Lung adenocarcinoma Homo sapiens CVCL_1511
A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
AC16 [Human hybrid cardiomyocyte] Normal Homo sapiens CVCL_4U18
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A) 21 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PT2385 Phase 2 [5]
Synonyms
ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 91754484
TTD: D0C9PZ
 Compound Name ISIS 298697 Investigative [6]
External Link
TTD: D00JHE
 Compound Name ISIS 298744 Investigative [6]
External Link
TTD: D01DDQ
 Compound Name ISIS 298746 Investigative [6]
External Link
TTD: D01ZCK
 Compound Name ISIS 298745 Investigative [6]
External Link
TTD: D07GVC
 Compound Name ISIS 298743 Investigative [6]
External Link
TTD: D09DCJ
 Compound Name ISIS 298702 Investigative [6]
External Link
TTD: D0B5LQ
 Compound Name ISIS 298700 Investigative [6]
External Link
TTD: D0C2IG
 Compound Name ISIS 175510 Investigative [6]
External Link
TTD: D0G9BP
 Compound Name ISIS 298699 Investigative [6]
External Link
TTD: D0L5ME
 Compound Name ISIS 298712 Investigative [6]
External Link
TTD: D0L9KW
 Compound Name ISIS 298711 Investigative [6]
External Link
TTD: D0SN5O
 Compound Name ISIS 298701 Investigative [6]
External Link
TTD: D0X8GB
 Compound Name (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol Investigative [7]
Synonyms
Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5712
TTD: D00REK
 Compound Name HIF-1alpha Phase 4 [8]
Synonyms
Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060
    Click to Show/Hide
External Link
CID: 5328127
TTD: D0B0AX
 Compound Name IT-101 Phase 3 [8]
External Link
TTD: D06PEW
 Compound Name 2-Methoxyestradiol Phase 2 [8]
Synonyms
ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene
    Click to Show/Hide
External Link
CID: 66414
TTD: D06NYA
DrugBank: DB02342
 Compound Name PX-478 Phase 1 [8]
Synonyms
685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di
    Click to Show/Hide
External Link
CID: 11234794
TTD: D06ZVO
DrugBank: DB06082
 Compound Name EZN-2968 Phase 1 [8]
External Link
TTD: D0NF5J
 Compound Name ENMD-1198 Phase 1 [8]
Synonyms
EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed
    Click to Show/Hide
External Link
CID: 11483754
TTD: D0Y5QD
DrugBank: DB05959
 Compound Name Pyrrolidine carboxamide derivative 1 Patented [8]
Synonyms
PMID26882240-Compound-22
    Click to Show/Hide
External Link
CID: 56684144
TTD: D0Q2SE
References
Ref 1 YBX1 promotes tumor growth by elevating glycolysis in human bladder cancer. Oncotarget. 2017 Jul 26;8(39):65946-65956. doi: 10.18632/oncotarget.19583. eCollection 2017 Sep 12.
Ref 2 N6-methyladenosine induced miR-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1. Mol Cancer. 2019 Dec 10;18(1):181. doi: 10.1186/s12943-019-1108-x.
Ref 3 Loss of m(6)A methyltransferase METTL3 promotes heart regeneration and repair after myocardial injury. Pharmacol Res. 2021 Dec;174:105845. doi: 10.1016/j.phrs.2021.105845. Epub 2021 Aug 21.
Ref 4 PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1alpha/VMP1 Axis in Pancreatic Cancer. Pancreas. 2021 Feb 1;50(2):227-234. doi: 10.1097/MPA.0000000000001747.
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6 US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
Ref 7 Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10. doi: 10.1016/j.bmcl.2007.09.005. Epub 2007 Sep 7.
Ref 8 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.